Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of C. difficile Vaccine with Novel Adjuvants in Healthy Adults
NCT05805826Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2023
- Primary completion
- Jun 2031
- Countries
- 1
01
Overview
Phase 2, randomised trial in Clostridioides difficile infection (CDI) (18 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants reporting local reactions, Percentage of participants reporting systemic events and 7 more. Started Mar 2023; status: active, not recruiting.
02
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT05805826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05805826.